These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 8124221)
1. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia. Caron PC; Scheinberg DA Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221 [TBL] [Abstract][Full Text] [Related]
2. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247 [TBL] [Abstract][Full Text] [Related]
3. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644 [TBL] [Abstract][Full Text] [Related]
4. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368 [TBL] [Abstract][Full Text] [Related]
5. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759 [TBL] [Abstract][Full Text] [Related]
6. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463 [TBL] [Abstract][Full Text] [Related]
7. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338 [TBL] [Abstract][Full Text] [Related]
8. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Matthews DC Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893 [TBL] [Abstract][Full Text] [Related]
10. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125 [TBL] [Abstract][Full Text] [Related]
11. Chimeric and humanized antibodies with specificity for the CD33 antigen. Co MS; Avdalovic NM; Caron PC; Avdalovic MV; Scheinberg DA; Queen C J Immunol; 1992 Feb; 148(4):1149-54. PubMed ID: 1737932 [TBL] [Abstract][Full Text] [Related]
13. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Frankel AE; Sievers EL; Scheinberg DA Cancer Biother Radiopharm; 2000 Oct; 15(5):459-76. PubMed ID: 11155818 [TBL] [Abstract][Full Text] [Related]
14. What happened to anti-CD33 therapy for acute myeloid leukemia? Jurcic JG Curr Hematol Malig Rep; 2012 Mar; 7(1):65-73. PubMed ID: 22109628 [TBL] [Abstract][Full Text] [Related]
15. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Co MS; Scheinberg DA; Avdalovic NM; McGraw K; Vasquez M; Caron PC; Queen C Mol Immunol; 1993 Oct; 30(15):1361-7. PubMed ID: 8232322 [TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328 [TBL] [Abstract][Full Text] [Related]
17. Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML. Sayar D; Burstein Y; Bielorai B; Toren A; Dvir R Pediatr Blood Cancer; 2010 Jul; 55(1):183-5. PubMed ID: 20310000 [TBL] [Abstract][Full Text] [Related]
18. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024 [TBL] [Abstract][Full Text] [Related]
19. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. Sutherland MK; Yu C; Lewis TS; Miyamoto JB; Morris-Tilden CA; Jonas M; Sutherland J; Nesterova A; Gerber HP; Sievers EL; Grewal IS; Law CL MAbs; 2009; 1(5):481-90. PubMed ID: 20065652 [TBL] [Abstract][Full Text] [Related]